Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

BMC Gastroenterology Pub Date : 2025-05-26 DOI:10.1186/s12876-025-03789-z

Minfang Lv, Ghavam Shafagh, Saiting Yu

{"title":"Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.","authors":"Minfang Lv, Ghavam Shafagh, Saiting Yu","doi":"10.1186/s12876-025-03789-z","DOIUrl":null,"url":null,"abstract":"Introduction: Several studies revealed that synbiotics have been beneficial in managing non-alcoholic fatty liver disease (NAFLD), but the findings are conflicting. We aimed to assess the effect of synbiotic supplementation on cardiovascular risk factors in patients with NAFLD.Methods: A thorough literature search was conducted to identify relevant studies up to July 2024, including publications from Pubmed, Embase, Cochrane, Scopus, and the Web of Science. Standardized mean difference (SMD) was used, and data with a 95% confidence interval (CI) were presented.Results: Sixteen RCTs were included, involving NAFLD patients and synbiotic supplementation. No significant effects were found on blood pressure (SBP: SMD - 6.68, p = 0.234; DBP: SMD - 4.31, p = 0.391), anthropometric measures (weight: SMD - 0.78, p = 0.126; BMI: SMD - 0.21, p = 0.182; waist circumference: SMD - 0.53, p = 0.095), or lipid profile (triglycerides: SMD - 3.67, p = 0.266; total cholesterol: SMD - 0.61, p = 0.059; low-density lipoprotein: SMD - 3.09, p = 0.215; high-density lipoprotein: SMD 0.49, p = 0.219). Synbiotics significantly reduced CRP levels (SMD - 1.83, p = 0.019) but had no significant effect on TNF-α (SMD - 1.95, p = 0.087). Synbiotic led to a significant reduction in weight following adjustment of publication bias (SMD - 1.16, p < 0.05).Conclusion: Overall, synbiotic supplementation does not significantly impact blood pressure, anthropometric indices, or lipid profile parameters in patients with NAFLD, except for a significant reduction in weight after adjusting for publication bias. Synbiotic supplementation significantly reduces CRP levels but has no effect on TNF-α.","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"407"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107792/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12876-025-03789-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Several studies revealed that synbiotics have been beneficial in managing non-alcoholic fatty liver disease (NAFLD), but the findings are conflicting. We aimed to assess the effect of synbiotic supplementation on cardiovascular risk factors in patients with NAFLD.

Methods: A thorough literature search was conducted to identify relevant studies up to July 2024, including publications from Pubmed, Embase, Cochrane, Scopus, and the Web of Science. Standardized mean difference (SMD) was used, and data with a 95% confidence interval (CI) were presented.

Results: Sixteen RCTs were included, involving NAFLD patients and synbiotic supplementation. No significant effects were found on blood pressure (SBP: SMD - 6.68, p = 0.234; DBP: SMD - 4.31, p = 0.391), anthropometric measures (weight: SMD - 0.78, p = 0.126; BMI: SMD - 0.21, p = 0.182; waist circumference: SMD - 0.53, p = 0.095), or lipid profile (triglycerides: SMD - 3.67, p = 0.266; total cholesterol: SMD - 0.61, p = 0.059; low-density lipoprotein: SMD - 3.09, p = 0.215; high-density lipoprotein: SMD 0.49, p = 0.219). Synbiotics significantly reduced CRP levels (SMD - 1.83, p = 0.019) but had no significant effect on TNF-α (SMD - 1.95, p = 0.087). Synbiotic led to a significant reduction in weight following adjustment of publication bias (SMD - 1.16, p < 0.05).

Conclusion: Overall, synbiotic supplementation does not significantly impact blood pressure, anthropometric indices, or lipid profile parameters in patients with NAFLD, except for a significant reduction in weight after adjusting for publication bias. Synbiotic supplementation significantly reduces CRP levels but has no effect on TNF-α.

查看原文本刊更多论文

合成抗生素对非酒精性脂肪肝患者心血管危险因素的影响：GRADE评估的系统回顾和荟萃分析

几项研究表明，合生剂对治疗非酒精性脂肪性肝病（NAFLD）有益，但研究结果相互矛盾。我们的目的是评估合成补充剂对NAFLD患者心血管危险因素的影响。方法：对截至2024年7月的相关研究进行全面的文献检索，包括Pubmed、Embase、Cochrane、Scopus和Web of Science的出版物。采用标准化均差（SMD），给出95%置信区间（CI）的数据。结果：纳入16项随机对照试验，涉及NAFLD患者和益生菌补充剂。对血压无显著影响(收缩压：SMD - 6.68, p = 0.234；DBP: SMD - 4.31, p = 0.391)，人体测量(体重：SMD - 0.78, p = 0.126；BMI: SMD - 0.21, p = 0.182；腰围：SMD - 0.53, p = 0.095)或血脂(甘油三酯：SMD - 3.67, p = 0.266；总胆固醇：SMD - 0.61, p = 0.059；低密度脂蛋白：SMD - 3.09, p = 0.215；高密度脂蛋白：SMD 0.49, p = 0.219)。合生剂显著降低CRP水平（SMD - 1.83, p = 0.019），但对TNF-α无显著影响（SMD - 1.95, p = 0.087）。综上所述，除了校正发表偏倚后体重有显著降低外，补充合成生物制剂对NAFLD患者的血压、人体测量指标或血脂参数没有显著影响。合成制剂可显著降低CRP水平，但对TNF-α无影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Gastroenterology 医学-胃肠肝病学

CiteScore

4.20

自引率

0.00%

发文量

465

审稿时长

6 months

期刊介绍： BMC Gastroenterology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of gastrointestinal and hepatobiliary disorders, as well as related molecular genetics, pathophysiology, and epidemiology.